GL 1001

Drug Profile

GL 1001

Alternative Names: GL1001; ORE 1001

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Ore Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; NSAID-induced ulcer; Obesity; Ulcerative colitis

Most Recent Events

  • 10 Sep 2009 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Ore Pharmaceuticals
  • 06 Dec 2008 Ore Pharmaceuticals completes phase I trial in Inflammatory disease
  • 06 Dec 2008 Adverse events data from a phase I trial in Inflammatory disease released by Ore Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top